In a mouse model of head and neck squamous cell carcinoma (HNSCC), combining anti-CTLA4 immunotherapy with the inhibition of Src family kinases (SFKs) showed a synergistic reduction in tumor growth. Here, CTLA4 is linked to head and neck squamous cell carcinoma.